Overview

Sunifiram (DM-235) is a synthetic piperazine-containing compound developed at the University of Firenze (Florence), Italy, as part of a structure-activity relationship program exploring simplified analogs of piracetam. Despite its structural origin in the racetam family, sunifiram is not technically classified as a racetam because it lacks the pyrrolidine nucleus — instead, it features a piperazine ring system. However, it shares the racetam class's fundamental mechanism of positive allosteric modulation of AMPA-type glutamate receptors, and it does so with extraordinary potency: sunifiram enhances AMPA receptor currents at concentrations approximately 1,000 times lower than piracetam, making it one of the most potent ampakine nootropics identified in preclinical research.

Sunifiram's mechanism involves binding to the AMPA receptor at the dimer interface between GluA1 and GluA2 subunits, stabilizing the channel in its open conformation and reducing receptor desensitization. This enhanced glutamatergic signaling facilitates long-term potentiation (LTP) in the hippocampus — the synaptic strengthening process essential for memory formation and consolidation. In animal studies, sunifiram reverses amnesia induced by scopolamine (a muscarinic antagonist), NBQX (an AMPA antagonist), and MK-801 (an NMDA antagonist), demonstrating broad anti-amnesic efficacy across multiple neurotransmitter systems. Additional mechanisms include activation of CaMKII (calcium/calmodulin-dependent protein kinase II) and PKCα — intracellular kinases that phosphorylate AMPA receptor subunits to enhance their conductance and membrane insertion — as well as increased glycine release that potentiates NMDA receptor function.

Sunifiram remains strictly an experimental research compound with no human clinical trials conducted to date. Despite this, it has gained popularity in the nootropic community, where users typically dose in the range of 4-10 mg sublingually (given its potency at microgram-to-milligram levels in animal models). The absence of human pharmacokinetic, safety, and efficacy data makes responsible dosing guidance impossible, and the compound's potent glutamatergic activity theoretically carries excitotoxicity risk at excessive doses. Sunifiram is often discussed alongside other ultra-potent nootropics including noopept (which operates through a different mechanism involving BDNF and NGF upregulation), unifiram (DM-232, a closely related structural analog with similar potency), and coluracetam (which enhances high-affinity choline uptake). It is not approved as a drug or supplement in any jurisdiction and is sold exclusively as a research chemical.

Mechanism of Action

Sunifiram (DM-235) is a synthetic piperazine-derived compound structurally related to the racetam family but approximately 1,000 times more potent than piracetam in enhancing cognitive function in animal models. Its primary mechanism involves modulation of glutamatergic neurotransmission at two key receptor subtypes: NMDA and AMPA receptors. At NMDA receptors, sunifiram acts at the glycine-binding site (the GluN1 subunit), enhancing receptor activation without directly stimulating it, thereby facilitating the NMDA receptor-dependent component of long-term potentiation (LTP) in the hippocampus.

Sunifiram's effects on AMPA receptors occur indirectly through activation of calcium/calmodulin-dependent protein kinase II (CaMKII) and protein kinase C alpha (PKCalpha). These kinases phosphorylate the AMPA receptor GluR1 subunit at Ser831, increasing single-channel conductance and promoting AMPA receptor trafficking to the postsynaptic membrane. This dual enhancement of both NMDA and AMPA receptor function produces a robust facilitation of LTP, the cellular mechanism underlying learning and memory formation.

In vivo studies have demonstrated that sunifiram reverses amnesia induced by scopolamine (anticholinergic), mecamylamine (nicotinic antagonist), and dizocilpine (NMDA antagonist) in passive avoidance and Morris water maze paradigms. The compound also increases acetylcholine release in the prefrontal cortex, suggesting secondary cholinergic facilitation. Sunifiram remains an experimental compound with no approved clinical applications, and human safety and efficacy data are essentially absent despite its popularity in the nootropics community.

Reconstitution Calculator

Research

Safety Profile

Safety Profile: Sunifiram

Common Side Effects

• Limited human safety data; effects reported primarily from anecdotal user reports
• Headache (common with ampakine-type compounds)
• Insomnia and overstimulation
• Anxiety and nervousness at higher doses
• Nasal congestion (when administered sublingually)
• Jaw clenching and bruxism reported by some users

Serious Adverse Effects

• No human clinical trials completed: Safety profile is largely unknown
• Theoretical excitotoxicity risk due to AMPA receptor potentiation (could lower seizure threshold)
• Unknown long-term neurotoxicity profile
• Unpredictable dose-response due to very high potency (active at microgram to low-milligram doses)
• Theoretical risk of neuronal damage from excessive glutamatergic signaling

Contraindications

• Epilepsy or seizure disorders (AMPA potentiation may lower seizure threshold)
• History of stroke or brain injury (excitotoxicity vulnerability)
• Pregnancy and lactation
• Children and adolescents
• Concurrent use of other ampakines or glutamate-modulating compounds

Drug Interactions

• Stimulants: Additive CNS excitation; increased seizure risk
• Other nootropics (racetams, ampakines): Overlapping glutamatergic mechanisms; unpredictable synergy
• Anticonvulsants: May reduce their efficacy
• SSRIs/SNRIs: Unknown interaction; theoretical concern for serotonin-glutamate crosstalk

Population-Specific Considerations

• Research compound only: Not approved for human use; available only through gray-market research chemical vendors
• Potency warning: Active at sub-milligram doses; accurate dosing requires precision scales and significant caution
• No established dosing protocol: User-reported doses vary widely (4–10 mg sublingually); no clinical guidance exists
• Risk-benefit: Very poor; no proven therapeutic benefit to offset unknown risks
• Nootropic community: Heavily discussed in online forums, but lack of clinical data makes all claims unverifiable

Pharmacokinetic Profile